Tvardi Therapeutics (NASDAQ:TVRD) Announces Quarterly Earnings Results

Tvardi Therapeutics (NASDAQ:TVRD) posted its quarterly earnings data on Tuesday. The company reported ($0.78) EPS for the quarter, FiscalAI reports.

Tvardi Therapeutics Stock Performance

Shares of TVRD stock traded down $0.02 during mid-day trading on Tuesday, hitting $3.18. The company’s stock had a trading volume of 39,850 shares, compared to its average volume of 45,925. The business has a 50-day moving average price of $3.81 and a 200 day moving average price of $9.00. The stock has a market cap of $29.83 million, a price-to-earnings ratio of -0.33 and a beta of 0.14. Tvardi Therapeutics has a 52-week low of $3.05 and a 52-week high of $43.65.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in TVRD. Geode Capital Management LLC purchased a new stake in Tvardi Therapeutics during the second quarter valued at approximately $2,617,000. JPMorgan Chase & Co. purchased a new stake in shares of Tvardi Therapeutics in the second quarter valued at $39,000. New York State Common Retirement Fund bought a new position in Tvardi Therapeutics during the 2nd quarter valued at about $92,000. Marshall Wace LLP bought a new position in shares of Tvardi Therapeutics during the second quarter valued at approximately $583,000. Finally, Slate Path Capital LP purchased a new stake in Tvardi Therapeutics in the second quarter worth $16,427,000. 44.66% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TVRD has been the subject of a number of recent analyst reports. Weiss Ratings reissued a “sell (e)” rating on shares of Tvardi Therapeutics in a research report on Monday, December 29th. Wall Street Zen upgraded Tvardi Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, March 8th. Finally, Lucid Cap Mkts raised shares of Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Tvardi Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $55.50.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.